Preliminary assessment of neck circumference in Benign Prostatic Hyperplasia in patients with metabolic syndrome

Abstract

ARTICLE INFO ______________________________________________________________ ______________________Objectives: To investigate the impact of neck circumference (NC) in the treatment of bening prostatic hyperplasia (BPH) patients with metabolic syndrome (MtS). Additionally, we determined dose response to alpha-blockers and cut-off values for NC and waist circumference (WC), in these patients. Materials and Methods: Non-randomized, open-labelled, and multi-centre study was conducted between March 2014 and September 2015. The BPH patients were enrolled and were divided into 2 groups: with MtS (Group 1; n=94) and without MtS (Group 2; n=103). Demographic data, anthropometric measurements, blood analyses, uroflowmetric parameters, post voiding residual urine (PVR), prostate volume, quality of life (QoL) index, NC and WC were recorded. Both groups were administered oral alphablockers and response to treatment was evaluated. Receiver-operating characteristic (ROC) curves were obtained and significant p was p<0.05. Results: In total, 197 patients were enrolled with mean age of 60.5±8.1 years. Mean NC and WC were higher in MtS patients (p<0.001). Uroflowmetry parameters and QoL indexes were comparable between groups before treatment. International prostate symptom score, uroflowmetry parameters, and QoL significant improved in Group 2 than Group 1, at 1 st and 6 th months of treatment with alpha-blockers. Success rate of treatment was significant higher in Group 2 than Group 1 (p<0.001). Cut-off values were 42.5cm and 113.5cm for NC and WC respectively, for response to alpha-blockers in BPH patients with MtS. Conclusions: MtS can be related with BPH and can negatively affect the response to alpha-blocker treatment. NC can be used for predicting response to alpha-blocker treatment in BPH patients with MtS.

The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and meta-analysis

“…In the final statistical analysis, there were 18 studies reported the PSA level [16,17,19,20,[22][23][24][25][26][27][28][30][31][32][33][34][35][36]. There was no statistical difference in PSA level between the presence of MetS and the absence of MetS (WMD ¼ 0.04; 95% Cl: À0.06 to 0.13; p ¼ .43; Figure 3).…”

“…The data of Qmax was gained in 8 studies [23,27,28,[30][31][32]35,36]. The Qmax of the MetS group was lower than the non-MetS group (WMD ¼ À0.48; 95% Cl: À0.77 to À0.19; p ¼ .001; Figure 4(a)).…”

“…The PVR data was only obtained from 3 relevant studies [23,32,35]. The pooled analysis indicated that the PVR of the MetS group was significantly higher than that of the non-MetS (WMD ¼ 8.28; 95% Cl: 5.90 to 10.67; p < .001; Figure 4(b)).…”

“…The QoL was reported in ten studies including 10,073 patients [17,19,20,[23][24][25][26][32][33][34]. Analysis of these studies showed that there was no statistical significance in QoL between patients with and without MetS (WMD ¼ À0.01; 95% Cl: À0.08 to 0.05; p ¼ .70; Figure 4(c)).…”

Androgen Deficiency and Progression of Benign Prostatic Hyperplasia in Patients With Metabolic Syndrome: Is There Any Controversy? (A Literature Review)

“…Эти особенности патогенеза ДГПЖ у больных с МС предполагают коррекцию терапии этих больных, особенно с учетом данных литературы о более низкой эффективности хирургического и медикаментозного лечения больных с ДГПЖ и МС по сравнению с паци-ентами без метаболических расстройств [70][71][72]. …”